GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic peptide made of six amino acids that stimulates your body to release more growth hormone. It works by mimicking ghrelin, the hormone your body naturally produces to signal hunger and trigger growth hormone secretion. GHRP-6 is not approved by the FDA for any medical condition, and it is banned in competitive sports by the World Anti-Doping Agency.
How GHRP-6 Works in the Body
GHRP-6 binds to the same receptor as ghrelin, known as the growth hormone secretagogue receptor. When it activates this receptor, it triggers a signaling cascade inside cells that ultimately tells the pituitary gland to release growth hormone into the bloodstream. In animal studies, a single injection raised plasma growth hormone levels roughly fivefold within 5 to 10 minutes.
What makes GHRP-6 interesting from a biological standpoint is that it doesn’t simply cause one large dump of growth hormone. Research in sheep showed it increased the frequency of natural growth hormone-releasing hormone pulses by about 50%, suggesting it works partly by amplifying the body’s own rhythmic secretion pattern rather than overriding it entirely. The initial spike in growth hormone appears to come from a more direct action on the pituitary, while the sustained effect involves changes higher up in the brain’s signaling chain.
Growth hormone itself isn’t the only thing that rises. Intravenous administration also increases cortisol, prolactin, and ACTH. These secondary hormonal effects are a key distinction between GHRP-6 and some of its alternatives.
Appetite Stimulation and Metabolic Effects
One of the most noticeable effects of GHRP-6 is a strong increase in hunger. This happens because the peptide activates neurons in the arcuate nucleus, a region deep in the brain that acts as a control center for appetite. Specifically, it switches on a group of neurons that produce signals promoting food intake, the same neurons that natural ghrelin targets. This is not a subtle side effect for most people. It can feel like an intense, urgent need to eat.
GHRP-6 also appears to influence insulin. Animal research published in the Journal of Endocrinology found that injection of GHRP-6 caused a temporary but significant rise in insulin levels, likely because ghrelin receptors exist on insulin-producing cells in the pancreas. The FDA has flagged a related concern: GHRP-6 may decrease insulin sensitivity, which could raise blood glucose over time. For anyone with existing blood sugar issues, this is a meaningful consideration.
Potential Tissue-Protective Effects
Most of the clinical interest in GHRP-6 centers on its potential to protect tissues from damage, particularly the heart. A 2024 study published in Frontiers in Pharmacology found that in rats given a chemotherapy drug known to damage the heart, GHRP-6 administered alongside the drug prevented the breakdown of heart muscle fibers and the dangerous dilation of the left ventricle. The researchers found it preserved heart function by bolstering cells’ antioxidant defenses, supporting the activity of a gene that helps cells survive stress, and keeping mitochondria intact.
The protective effects extended beyond the heart. Animals treated with GHRP-6 showed significantly less liver congestion and lung damage compared to those given only a saline placebo. Liver enzyme levels, a marker of liver injury, were also lower in the GHRP-6 group. Separate research has explored GHRP-6 for wound healing, with one study reporting it enhanced the healing process and improved the cosmetic appearance of wounds.
These findings are promising but remain in the animal research stage. No clinical trials have established GHRP-6 as a treatment for any of these conditions in humans.
How GHRP-6 Compares to Similar Peptides
GHRP-6 belongs to a family of growth hormone-releasing peptides, and it’s often compared to two close relatives: GHRP-2 and ipamorelin. The key differences come down to selectivity and side effects.
- GHRP-6 produces a strong growth hormone release but also raises cortisol and prolactin levels and causes significant hunger. It’s considered the least selective of the three, meaning it triggers the broadest range of hormonal responses.
- GHRP-2 is similar to GHRP-6 in potency and also raises cortisol and prolactin, though some users report slightly less appetite stimulation.
- Ipamorelin is considered the most selective option. It stimulates growth hormone release without measurably affecting cortisol or prolactin. It also metabolizes more slowly, staying active in the bloodstream longer. Researchers often describe it as a “gentle peptide” because it appears to affect only the growth hormone axis.
For someone primarily concerned about the hormonal side effects of GHRP-6, particularly the cortisol and prolactin increases, ipamorelin represents the cleaner alternative. For someone who actually wants the appetite-stimulating effect (certain athletes trying to gain weight, for instance), GHRP-6’s aggressive hunger signal is a feature rather than a bug.
Regulatory and Legal Status
GHRP-6 has no FDA approval for any human medical use. In September 2023, the FDA specifically flagged it as a bulk drug substance that may present significant safety risks when used in compounded medications. The agency cited concerns about immunogenicity (the potential for the body to mount an immune reaction against the peptide), effects on cortisol, and decreased insulin sensitivity leading to higher blood glucose.
In competitive athletics, GHRP-6 is classified under the World Anti-Doping Agency’s S2 category: Peptide Hormones, Growth Factors, Related Substances and Mimetics. It is prohibited at all times, both in and out of competition. All GHRPs share this classification.
Why Timing and Fasting Matter
Blood sugar and insulin levels at the time of administration influence how much growth hormone GHRP-6 actually releases. Elevated insulin blunts the growth hormone response, which is why protocols typically call for use on an empty stomach. Eating a meal, particularly one high in carbohydrates, raises insulin and can significantly reduce the peptide’s effectiveness. The general principle is that lower baseline insulin allows for a larger growth hormone pulse, which is why fasted administration is considered standard practice among users.
GHRP-6 itself can transiently raise insulin levels after injection, creating a brief window where repeated dosing would yield diminishing returns. This is one reason users typically space doses several hours apart rather than taking them back to back.